Aidea Pharma(SH:688488)2025-04-29 15:53Financial Performance - The company's operating revenue for Q1 2025 reached ¥197,860,545.62, representing a 113% increase compared to ¥92,893,957.00 in the same period last year[4] - Net profit attributable to shareholders was ¥15,581,976.25, a significant turnaround from a loss of ¥13,606,889.35 in the previous year[4] - The net cash flow from operating activities improved to ¥39,754,170.62, compared to a negative cash flow of ¥70,322,344.42 in the same period last year[4] - Basic and diluted earnings per share increased to ¥0.04, up from a loss of ¥0.03 per share in the previous year[4] - The company achieved a total operating revenue of CNY 197.86 million in Q1 2025, a significant increase of 112.6% compared to CNY 92.89 million in Q1 2024[23] - The operating profit for Q1 2025 was CNY 31,827,713.39, a turnaround from an operating loss of CNY 16,860,520.56 in the same period last year[24] - Total comprehensive income for Q1 2025 was CNY 25,609,979.12, compared to a comprehensive loss of CNY 13,606,889.35 in Q1 2024[25] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥1,895,106,059.27, a 1.37% increase from ¥1,869,563,338.32 at the end of the previous year[5] - The company’s total assets reached CNY 1.90 billion as of March 31, 2025, compared to CNY 1.87 billion at the end of 2024, indicating a growth of 1.3%[20] - The company’s total liabilities were CNY 802.64 million as of March 31, 2025, slightly up from CNY 802.48 million at the end of 2024, reflecting a marginal increase of 0.2%[22] Research and Development - Research and development expenses totaled ¥19,484,687.54, accounting for 9.85% of operating revenue, down from 21.87% in the previous year, a decrease of 12.02 percentage points[5] - Research and development expenses decreased to CNY 15,711,444.19 in Q1 2025 from CNY 17,748,750.48 in Q1 2024, reflecting a reduction of about 11.5%[24] - The company is developing long-acting innovative HIV drugs and has completed pre-toxicology tests for a new molecule[16] - The company has initiated IND registration for a long-acting new molecule and completed the production of validation batches[15] - The company is expanding its pipeline for pre-exposure prophylaxis in the HIV field, focusing on long-acting drug development[16] Market and Product Development - The increase in operating revenue was primarily due to the consolidation of Nanjing Nanda Pharmaceutical Co., which contributed an additional ¥92,237,500 in revenue, and a rise in HIV drug business revenue by ¥27,010,700[7] - Revenue from the HIV new drug business reached CNY 62.72 million, marking a year-on-year increase of 75.64%[12] - The company successfully established a commercial operation system for HIV innovative drugs, integrating product characteristics with market demand[12] - The phase III clinical trial of the drug Ainomi has shown positive results, with over 95% adherence and viral suppression rates maintained from 0 to 144 weeks[13] - The new integrase inhibitor ACC017 has received a patent and is progressing to phase II clinical trials, with initial results indicating good safety and efficacy[14] - The company has completed the enrollment of participants for a phase II clinical study in treatment-experienced populations[15] - The company is actively promoting its new drug pipeline and enhancing its market presence through strategic adjustments and team building[12] - The company is actively expanding its overseas market for HIV innovative products and human protein products, with a focus on Africa and Southeast Asia[17] Cash Flow and Financial Health - The company’s cash and cash equivalents increased to CNY 422.73 million as of March 31, 2025, compared to CNY 335.34 million at the end of 2024, reflecting a growth of 25.9%[20] - The company’s accounts receivable stood at CNY 127.35 million as of March 31, 2025, slightly down from CNY 139.14 million at the end of 2024, a decrease of 8.5%[20] - The company’s inventory increased to CNY 271.74 million as of March 31, 2025, compared to CNY 254.97 million at the end of 2024, representing a growth of 6.6%[20] - The company raised CNY 200,000,000.00 through borrowings in Q1 2025, compared to CNY 140,300,000.00 in Q1 2024[27] - The company reported an investment income loss of CNY 225,518.40 in Q1 2025, contrasting with a gain of CNY 7,573,963.00 in Q1 2024[24] - The company’s sales expenses increased to CNY 57,867,148.60 in Q1 2025 from CNY 21,191,476.67 in Q1 2024, marking an increase of approximately 173%[24]